

# Biomarker Deals: Terms, Value and Trends, 2008-2018

https://marketpublishers.com/r/B6CDD33C584EN.html

Date: November 2018

Pages: 116

Price: US\$ 1,375.00 (Single User License)

ID: B6CDD33C584EN

### **Abstracts**

#### Report Scope:

This report represents a current and important business tool to evaluate terms and conditions of licensing, acquisitions and partnerships deals in the biomarker sector. The geographic scope of this study covers the U. S. and companies worldwide. The report identifies the main elements in licensing, acquisitions and partnership deals in the biomarker industry.

#### Report Includes:

43 data tables and 42 additional tables

An overview of the current state of the biomarker industry, recent licensing deals, and collaborations and acquisitions in the market, including detailed analysis of deals structure and their potential values

Information about significant players in this field of study, trends and obstacles, and other information affecting biomarker market development

Review of business terms and conditions of deals in the biomarker market, with focus on major trends in biomarker deal making, the companies involved and analysis of further potential in out-licensing, collaboration and acquisition opportunities

Essential information to a prospective dealmaker about partnering in the research, development and commercialization of biomarker technologies and products.



Identification of the main elements in licensing, acquisitions and partnership deals in the biomarker industry

Coverage of research methodology employing a triangulating approach and significant details of patent search and analysis, clinical trial search and analysis et al.

Details of various types of biomarkers deals and milestone payments and their value in different deals

Examination of competitive landscape and detailed profiles of major companies developing biomarkers, including bioMerieux SA, IntegraGen SA, MDxHealth, Myriad Genetics, Protagen AG and Qiagen



#### **Contents**

#### **CHAPTER 1 INTRODUCTION=**

Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources and Methodology
Intended Audience
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports

#### **CHAPTER 2 SUMMARY AND HIGHLIGHTS=**

#### CHAPTER 3 MARKET AND TECHNOLOGY BACKGROUND=

Biomarker Definition and Classification
Biomarker Applications
Biomarker Identification and Detection Technologies
Steps in Biomarker Development
Biomarker Market Analysis and Evaluation
Global Biomarker Market Value and its Segmentation
Oncology-Related Biomarkers Sector
Cardiovascular Diseases Biomarker Sector
Neurological Disorders and Other Diseases Biomarkers Sector
Market Participants in the Biomarkers Space

# CHAPTER 4 BIOMARKERS MARKET - LICENSING, ACQUISITIONS, COLLABORATIONS DEAL ANALYSIS=

Licensing Deals in the Biomarkers Market, 2008-2018
Licensing Deal Definition and General Structure
Valuation and Payment Structure
Analysis of Licensing Deals in the Biomarkers Market, 2008-2018
Acquisition Deals in the Biomarkers Market, 2008-2018
Acquisition Deal Definition and General Structure
Analysis of Acquisition Deals in the Biomarkers Market, 2008-2018
Partnerships/Collaboration Deals in the Biomarkers Market, 2008-2018

Biomarker Deals: Terms, Value and Trends, 2008-2018



Collaboration Deal Definition and General Structure

Analysis of Partnership/collaboration Deals in the Biomarkers Market, 2008-2018 Analysis of Different Aspects of Licensing, Acquisition and Collaboration Deals in the Biomarkers Market

Analysis of Licensing Deals Structure in the Biomarkers Market, 2008-2018
Analysis of Acquisition Deals Structure in the Biomarkers Market, 2008-2018
Analysis of Collaboration Deals Structure in the Biomarkers Market, 2008-2018
Biomarker Market Participants Active in Licensing, Acquisitions and
Partnership/Collaboration Deals, 2008-2018

Qiagen

bioMerieux

MDxHealth

Myriad Genetics

# CHAPTER 5 IMPACT OF OTHER MARKETS AND CLINICAL TRIALS ON LICENSING, ACQUISITION AND COLLABORATIONS IN THE BIOMARKERS MARKET=

Cancer Diagnostics as Market Potential for Exosome-Based Diagnostics Product Development

Prostate Cancer as Potential for Biomarker Development

Breast Cancer as Potential for Biomarker Development

Bladder Cancer as Potential for Biomarker Development

Ovarian Cancer as Potential for Biomarker Development

Lung Cancer as Potential for Biomarker Development

CNS Disorders and Neurodegeneration Diseases as Market Potential for Biomarker Development

Cardiovascular Diseases as Market Potential for Biomarker Development

Organ Transplantation as Market Potential for Biomarker Development in Immune Disorders

Clinical Trials as Indicator for Biomarker Market Development

#### **CHAPTER 6 PATENT REVIEW/NEW DEVELOPMENTS=**

**CHAPTER 7 MARKET SUMMARY=** 

#### **CHAPTER 8 COMPANY PROFILES=**

**BIOMERIEUX S.A.=** 

Biomarker Deals: Terms, Value and Trends, 2008-2018



INTEGRAGEN SA=
MDX HEALTH=
MYRIAD GENETICS=
PROTAGEN AG=

**QIAGEN** 



# **List Of Tables**

#### LIST OF TABLES

Summary Table: Global Biomarkers Licensing, Acquisition and Partnership Deals

Market, by Type, 2014-2018

Table 1: Biomarker Classification

Table 2: Applications of Biomarkers

Table 3: Common Techniques Used for Biomarker Identification

Table 4: Global Biomarkers Market, Through 2023

Table 5: Global Biomarker Market Share, by Application, 2018

Table 6: Examples of Cancer Biomarkers for Therapy Selection and Monitoring

Table 7: Examples of Current Cancer-Associated Antigens/Biomarkers Used in Cancer Diagnosis

Table 8: Liquid Biopsy Market, 2017 and 2018

Table 9: Global Cancer Biomarkers Market, Through 2023

Table 10: Examples of Cardiovascular Biomarkers Used for Clinical Diagnosis

Table 11: Global Cardiovascular Biomarkers Market, Through 2023

Table 12: Examples of Neurological Biomarkers for Clinical Diagnosis

Table 13: Global Biomarkers Market, by Application Sector, Through 2023

Table 14: Examples of Biomarkers Market Participants

Table 15: Overview of Common Payment Forms in Licensing Deal

Table 16: Number of Biomarker Licensing Deals in Different Biotech Sectors,

2008-2018

Table 17: Share of Biomarker Licensing Deals in Different Biotech Sectors, by Year,

2008-2018

Table 18: Example of Licensing Deals, 2008-2018

Table 19: Number of Biomarker Licensing Deals in Different Pathological Sectors,

2008-2018

Table 20: Share of Biomarker Licensing Deals in Different Pathological Sectors,

2008-2018

Table 21: Purpose of Biomarker Licensing Deals, 2008-2018

Table 22: Share of Licensing Deals Between Companies and Academic Institutions vs.

Between Two Companies, 2008-2018

Table 23: Share of Biomarker Licensing Deals in North America vs. Europe, 2008-2018

Table 24: Total Number of Biomarker Acquisition Deals in Different Biotech Sectors,

2008-2018

Table 25: Share of Biomarker Acquisition Deals in Different Biotech Sectors, by Year,

2008-2018



Table 26: Examples of Acquisition Deals, 2008-2018

Table 27: Number of Biomarker Acquisition Deals in Different Pathological Sectors,

2008-2018

Table 28: Share of Biomarker Acquisition Deals in Different Pathological Sectors,

2008-2018

Table 29: Purpose of Biomarkers Acquisition Deals, 2008-2018

Table 30: Share of Biomarker Acquisition Deals in North America Vs. Europe,

2008-2018

Table 31: Total Number of Biomarker Collaboration Deals in Different Biotech Sectors.

2008-2018

Table 32: Share of Biomarker Collaboration Deals in Different Biotech Sectors, by Year,

2008-2018

Table 33: Examples of Partnership/Collaboration Deals in the Biomarkers Market,

2008-2018

Table 34: Number of Biomarker Collaboration Deals in Different Pathological Sectors,

2008-2018

Table 35: Share of Biomarker Collaboration Deals in Different Pathological Sectors,

2008-2018

Table 36: Purpose of Biomarkers Collaboration Deals, 2008-2018

Table 37: Share of Collaboration Deals Between Companies and Academic Institutions

vs. Between Two Companies, 2008-2018

Table 38: Share of Biomarker Collaborations/Partnerships in North America vs. Europe,

2008-2018

Table 39: Examples of Upfront Payments in Licensing Deals, 2008-2018

Table 40: Examples of Milestone and Royalty Payments in Licensing Deals, 2008-2018

Table 41: Examples of Termination Condition in Licensing Biomarkers Deals,

2008-2018

Table 42: Global Biomarkers Licensing Deals Market, 2014-2018

Table 43: Examples of Acquisition Deals Values in the Biomarkers Market, 2008-2018

Table 44: Global Value of Biomarkers Acquisition Deals, 2014-2018

Table 45: Examples of Upfront Payments and Total Value in Collaboration Deals,

2008-2018

Table 46: Share of Upfront Payments from Total Value in Collaboration Deals,

2008-2018

Table 47: Examples of Milestones and Royalty Payments in Collaboration Deals,

2008-2018

Table 48: Examples of Termination Conditions in Collaboration Biomarkers Deals,

2008-2018

Table 49: Global Value of Biomarkers Partnership Deals, 2014-2018

Biomarker Deals: Terms, Value and Trends, 2008-2018



Table 50: Examples of Biomarker Market Participants in Licensing, Collaboration and Acquisition Deals, 2008-2018

Table 51: Examples of Biomarker Market Participants and Total Number of Deals

Related to Biomarker Activity, 2008-2018

Table 52: Financial Data for Qiagen, 2015-2017

Table 53: Financial Data for bioMerieux, 2015-2017

Table 54: Financial Data for MDxHealth, 2015-2017

Table 55: Financial Data for Myriad Genetics, 2015-2017

Table 56: Statistics for Prostate Cancer, 2017

Table 57: Global Prostate Cancer Diagnostics Market and Related Cost, 2018-2023

Table 58: Statistics for Breast Cancer, 2017

Table 59: Global Market for Breast Cancer Diagnostics, Through 2019

Table 60: Statistics for Bladder Cancer, 2017

Table 61: Global Market for Bladder Cancer Diagnostics, 2017

Table 62: Statistics for Ovarian Cancer, 2017

Table 63: Global Ovarian Cancer Diagnostics Market, 2017

Table 64: Statistics for Lung Cancer, 2017

Table 65: Global Lung Cancer Diagnostics Market, 2017

Table 66: U.S. Statistics Data for Alzheimer's, 2017

Table 67: Global Market for Alzheimer's Disease Therapeutics and Diagnostics,

Through 2020

Table 68: U.S. Statistics Data for Cardiovascular Diseases, 2017

Table 69: Global Cardiovascular Diagnostics Market, 2017

Table 70: Global Organ and Tissue Transplantation Products and Devices Market,

Through 2020

Table 71: Number of Clinical Trials on Biomarkers Per Year, 2008-2017

Table 72: Search Analysis for Clinical Trials Using Specific Keywords

Table 73: Distribution of Clinical Trials on Biomarkers Based on Different Stages of

Clinical Trials

Table 74: Analysis of Biomarker Clinical Trials, Based on Sponsor

Table 75: Examples of Clinical Trials Related to Biomarker R&D

Table 76: Number of Clinical Trials Sponsored by Some Biomarker Market Participants

Table 77: Number of Patents and Patent Applications Filed on Biomarkers, by Year,

2008-2017

Table 78: Examples of Patents and Patent Applications Filed on Biomarkers, 2008-2017

Table 79: Search Analysis for Patents and Patent Applications Using Keyword

Combinations

Table 80: Number of Patents and Patent Applications, by Company

Table 81: Examples of Patents and Patent Applications Filed on Biomarkers, by



# Company

Table 82: Global Value of Biomarkers Licensing, Acquisition and Partnership Deals, by

Type, 2014-2018

Table 83: Share of Biomarker Licensing Deals in Different Pathological Sectors,

2008-2018

Table 84: Examples of Biomarker Market Participants and Total Number of Deals

Related to Biomarker Activity



# **List Of Figures**

#### LIST OF FIGURES

Summary Figure: Global Biomarkers Licensing, Acquisition and Partnership Deals Market, by Type, 2014-2018

Figure 1: Schematic Presentation of Biomarker Development Process During Drug Development

Figure 2: Global Biomarkers Market, 2016-2023

Figure 3: Number of Biomarker Licensing Deals in Different Biotech Sectors, 2008-2018

Figure 4: Share of Biomarker Licensing Deals in Different Biotech Sectors, by Year, 2008-2018

Figure 5: Share of Biomarker Licensing Deals in Different Pathological Sectors, 2008-2018

Figure 6: Purpose of Biomarker Licensing Deals, 2008-2018

Figure 7: Share of Licensing Deals Between Companies and Academic Institutions vs.

Between Two Companies, 2008-2018

Figure 8: Share of Biomarker Licensing Deals in North America vs. Europe, 2008-2018

Figure 9: Total Number of Biomarker Acquisition Deals in Different Biotech Sectors, 2008-2018

Figure 10: Share of Biomarker Acquisition Deals in Different Biotech Sectors, by Year, 2008-2018

Figure 11: Share of Biomarker Acquisition Deals in Different Pathological Sectors, 2008-2018

Figure 12: Purpose of Biomarkers Acquisition Deals, 2008-2018

Figure 13: Share of Biomarker Acquisition Deals in North America Vs. Europe, 2008-2018

Figure 14: Total Number of Biomarker Collaboration Deals in Different Biotech Sectors, 2008-2018

Figure 15: Share of Biomarker Collaboration Deals in Different Biotech Sectors, by Year, 2008-2018

Figure 16: Share of Biomarker Collaboration Deals in Different Pathological Sectors, 2008-2018

Figure 17: Purpose of Biomarkers Collaboration Deals, 2008-2018

Figure 18: Share of Collaboration Deals Between Companies and Academic Institutions vs. Between Two Companies, 2008-2018

Figure 19: Share of Biomarker Collaboration/Partnerships in North America vs. Europe, 2008-2018

Figure 20: Global Biomarkers Licensing Deals Market, 2014-2018



Figure 21: Global Biomarkers Acquisition Deals Market, 2014-2018

Figure 22: Global Biomarkers Partnership Deals Market, 2014-2018

Figure 23: Examples of Biomarker Market Participants and Total Number of Deals

Related to Biomarker Activity, 2008-2018

Figure 24: Number of Clinical Trials on Biomarkers Per Year, 2008-2017

Figure 25: Search Analysis for Clinical Trials Using Specific Keywords

Figure 26: Distribution of Clinical Trials on Biomarkers Based on Different Stages of Clinical Trials

Olli licai Triais

Figure 27: Number of Patents and Patent Applications Filed on Biomarkers, by Year,

2008-2017

Figure 28: Search Analysis for Patents and Patent Applications Using Keyword

Combinations

Figure 29: Global Biomarkers Licensing, Acquisition and Partnership Deals Market, by

Type, 2014-2018



#### I would like to order

Product name: Biomarker Deals: Terms, Value and Trends, 2008-2018

Product link: <a href="https://marketpublishers.com/r/B6CDD33C584EN.html">https://marketpublishers.com/r/B6CDD33C584EN.html</a>

Price: US\$ 1,375.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

# **Payment**

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <a href="https://marketpublishers.com/r/B6CDD33C584EN.html">https://marketpublishers.com/r/B6CDD33C584EN.html</a>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <a href="https://marketpublishers.com/docs/terms.html">https://marketpublishers.com/docs/terms.html</a>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970